6 marketing jobs found in Bridgewater

At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives.

At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Managing Complexity. Improving Lives.

Inizio Engage is a strategic, commercial, and creative engagement partner that specializes in healthcare. Our passionate, global workforce augments local expertise and diverse mix of skills with data, science, and technology to deliver bespoke engagement solutions that help clients reimagine how they engage with their patients, payers, people and providers

Inizio Engage is a strategic, commercial, and creative engagement partner that specializes in healthcare. Our passionate, global workforce augments local expertise and diverse mix of skills with data, science, and technology to deliver bespoke engagement solutions that help clients reimagine how they engage with their patients, payers, people and providers

Bausch Health Companies Inc. is a global, diversified pharmaceutical company whose mission is to improve people’s lives with our pharmaceutical products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, and international pharmaceuticals. With our leading durable brands, we are delivering on our commitments to patients, health care providers, other stakeholders and society as we build an innovative company dedicated to advancing global health.

Amarin Corporation plc (“Amarin”) is a rapidly growing pharmaceutical company developing and selling therapeutics to improve cardiovascular health. Amarin, a publicly traded company (NASDAQ: AMRN) with approximately 900 employees, is headquartered in Dublin, Ireland and has its US operations (Amarin Pharma Inc.) based in Central New Jersey. Amarin has successfully developed, registered and launched VASCEPA® in the U.S. market with a network of third-party companies aligned with Amarin to advance commercialization of VASCEPA® globally. In the U.S., VASCEPA® was launched in 2013 for its initial indication of as a treatment of Very High Triglycerides (i.e. patients with TG levels ≥ 500mg/dL). In November 2018, unprecedented clinical results were announced from a landmark global cardiovascular outcomes study in which VASCEPA®demonstrated a significantly lower risk of cardiovascular events beyond the current standard of care for cholesterol management....